Is cisplatin still the best platinum compound in non-small-cell lung cancer?
Authors:
Open Access
- 1 October 2002
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 13 (10) , 1515-1517
Abstract
Lung cancer remains the leading cause of cancer-related death in industrialized countries and is therefore a major health problem for western societies [1]. In the past, the role of chemotherapy for non-small-cell lung cancer (NSCLC) has been extensively debated and the lack of activity of most cytotoxic compounds, used as single agents or in combination, led a large part of the medical community to refute chemotherapy for patients with NSCLC. Nevertheless, anecdotical reports and occasional prospective studies suggested a potential benefit of chemotherapy in advanced NSCLC in the 1970s.Keywords
This publication has 18 references indexed in Scilit:
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trialThe Lancet, 2001
- The Hallmarks of CancerCell, 2000
- A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatious germ cell tumorsAnnals of Oncology, 1996
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993
- Editor's forewordCurrent Problems in Cancer, 1991
- Making Chemotherapy EasierNew England Journal of Medicine, 1990
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990